NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Stillwell888,

I believe you are on the right track with your thought process. DCVax-L requires tumor lysate so L as it exists now may not be suitable for a vaccine such as the one you suggested, however, a partially allogenic (created outside of self vaccine) based on cultured T-cells harvested after DCVax-L treatment might be cloned and banked as a way to begin the process of creating an allogenic activated T-cell/DC primed vaccine that targets all critcal targets found in any given patient and will also have the capacity to hunt down mutated neo antigens.